NanoVax Therapeutics

NanoVax is a biotechnology company focused on the development of next-generation vaccines using its proprietary Protein Cage Nanoparticle (PCN) platform. The company's technology utilizes self-assembling protein architectures, often derived from thermophilic organisms, to create highly stable and modular vaccine delivery systems. These nanoparticles can be engineered to display a wide array of antigens, enhancing the immune response while maintaining a favorable safety profile. NanoVax primarily targets infectious diseases, with early-stage programs focused on seasonal influenza and respiratory syncytial virus (RSV). The company operates as a spin-off from research conducted at Montana State University.